Abbott Diagnostics generates approximately $12 billion in IVD revenues in 2025, with leading positions in immunoassay, clinical chemistry, molecular diagnostics, and point-of-care testing across its Core Laboratory and Rapid Diagnostics divisions. The Alinity family — Alinity c for clinical chemistry, Alinity i for immunoassay, and Alinity m for molecular — represents Abbott's fully integrated laboratory automation strategy. The ID NOW platform received CE marking for its 2.0 enhanced version in January 2025, optimized for COVID-19 and flu dual detection, with over 50,000 instruments deployed globally. Abbott's BinaxNOW rapid antigen portfolio demonstrated the commercial power of decentralized diagnostics at population scale. Abbott reports 9.5-10% organic sales growth with $1.65-$1.68 billion in Q1 2025 revenue guidance.
This report provides significant competitor information, analysis, and insight critical to the development and implementation of effective marketing and R&D programs.
Topics Covered
• Strategic Directions — Alinity Consolidation, ID NOW Expansion, and POC Leadership Through 2030
• Financial Performance — Revenue, Revenue by Segment, Revenue by Geography, EBITDA, and R&D 2023-2025
• SWOT Analysis — Competitive Advantages, Structural Vulnerabilities, Opportunities, and Risks
• Technological Know-How — Alinity, ID NOW, BinaxNOW, and Abbott Diagnostics IP
• Latest Products and Services — Platform Launches, Menu Expansions, and Innovation Pipeline
• M&A — Acquisitions, Divestitures, and Partnerships 2023-2025
• Marketing Tactics — Reagent Rental Strategy, GPO Positioning, and Channel Approach
• Organization and Management — Leadership, Structure, and Workforce
Table of Contents
1. Executive Summary
2. Strategic Directions
3. Financial Performance
4. SWOT Analysis
5. Technological Know-How
6. Latest Products and Services
7. M&A
8. Marketing Tactics
9. Organization and Management
10. Appendix
List of Tables
Table 1. Abbott Diagnostics — Key Financial Metrics Summary 2023-2025
Table 2. Abbott Diagnostics — Revenue by Segment 2023-2025
Table 3. Abbott Diagnostics — Revenue by Geography 2023-2025
Table 4. Abbott Diagnostics — R&D Investment 2023-2025
Table 5. Abbott Diagnostics — SWOT Analysis
Table 6. Abbott Diagnostics — Core Technology Capabilities and Key Platforms
Table 7. Abbott Diagnostics — Key Analyzers and Reagent Portfolio
Table 8. Abbott Diagnostics — M&A Activity Summary 2023-2025
Table 9. Abbott Diagnostics — Key Management and Leadership
Table 10. Abbott Diagnostics — Strategic Priorities 2025-2030
